All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How should we treat older patients with ALL?
How should we treat older patients with ALL?
Jabbour starts by outlining the reasons why older patients with ALL are challenging to treat. He then goes on to discuss two newly available antibody drugs, blinatumomab and Inotuzumab, which are more tolerable in older patient populations.
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox